Everything tagged "dilution" across the TickerSpark archives.
Biomerica's $2.23 million private placement adds shares while the FY2026 filing still carries going-concern language. With revenue down 16.2% and a $3.77 million net loss, the raise buys time but does not establish a turnaround.
Biomerica's $2.23 million financing extends its runway, but it adds roughly 30% to the pre-deal share count without proving the business is turning. With severe losses, negative cash flow, and the stock still below its 200-day average, BMRA remains a dilution trade rather than a turnaround.
Intel's roughly $20 billion stock raise buys time for its foundry push, but it also makes shareholders finance a strategy whose biggest customer proof point is still ahead. With a -19.8% net margin and a 133.71x EV/EBITDA multiple, the turnaround has not earned this valuation yet.
AAOI's demand story is real, but the $600 million ATM turns capacity expansion into a dilution and return-on-capital problem. With a 14.49x sales multiple and a -9.6% net margin, the stock is priced for flawless execution before the new shares even arrive.
BGDE has beaten technology by 309 percentage points this year, but its next defining event is a financing one: Series D holders can start converting Aug. 30 at 95% of the lowest five-day VWAP. The AI/HPC plan is real, yet the registered resale supply makes us fade the rally until the market proves it can absorb the dilution.
NBIS is growing fast, but its $5.0 billion convertible offering and $2.8 billion share sale have made financing the stock's immediate risk. The AI demand is real; the dilution burden is arriving faster than the profits.
OTLK's $5.81 million insider buying is a real vote of confidence, but the company is still funding an approved product with fresh equity. A $55 million stock-and-warrant offering, a 600 million share authorization and ongoing losses keep dilution ahead of durable commercial proof.
OTLK has a real FDA-approved product, but the shareholder-approved expansion to 600 million authorized shares makes dilution the dominant trade setup. The August offering shows that financing pressure survived the regulatory victory and is already reaching common holders.
Rivian beat Q2 delivery expectations and lifted 2026 guidance, yet the company still needed a 75 million-share offering for roughly $1.2 billion. With Q1 free cash flow at negative $1.075 billion, the R2 ramp remains a financing problem before it becomes a durable profit story.
AST SpaceMobile’s latest financing changed the argument around the stock. The launch story is getting more credible, but the market is now focused on whether ASTS can fund a capital-heavy constellation without making shareholders pay for it.
The market is obsessing over Gloo's fresh share sale and missing the more important signal: management is still guiding to EBITDA breakeven in Q3 and profitability in Q4 while insiders have lined up at least $6.0 million for the deal. At 0.50x sales after a 47.1% YTD collapse, this looks more like a stressed setup around dilution than a broken operating story.
Rivian’s latest drop looks more like financing shock than a collapse in the operating story. The update that matters most right now was a Q2 delivery beat and a raised full-year outlook, and that is not what a broken demand story looks like.
Generate AI research on any ticker — grades, price targets, and full analysis in minutes.
Open the GeneratorCancel anytime